Yumanity Therapeutics (FRA:8IY) Debt-to-Equity : 0.04 (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Debt-to-Equity?

Yumanity Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.21 Mil. Yumanity Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.00 Mil. Yumanity Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2022 was €5.53 Mil. Yumanity Therapeutics's debt to equity for the quarter that ended in Sep. 2022 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Yumanity Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:8IY's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Yumanity Therapeutics Debt-to-Equity Historical Data

The historical data trend for Yumanity Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Debt-to-Equity Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Debt-to-Equity

-0.17

0.63

1.18

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial							0.93	1.18	0.93	0.14	0.04

Competitive Comparison of Yumanity Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Yumanity Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yumanity Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's Debt-to-Equity falls into.

Yumanity Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Yumanity Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.662	+	14.843)	/	20.795
	=	1.18

Yumanity Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.206	+	0)	/	5.531
	=	0.04

Yumanity Therapeutics (FRA:8IY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Yumanity Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines